Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
JAMA ; 330(11): 1094-1096, 2023 09 19.
Artículo en Inglés | MEDLINE | ID: mdl-37589985

RESUMEN

This study reviewed public comments for all Medicare National Coverage Determinations between June 2019 and 2022 on select pulmonary and cardiac devices to determine whether financial conflicts of interest were disclosed.


Asunto(s)
Conflicto de Intereses , Equipos y Suministros , Cobertura del Seguro , Medicare , Anciano , Humanos , Conflicto de Intereses/economía , Equipos y Suministros/economía , Medicare/economía , Medicare/ética , Estados Unidos , Cobertura del Seguro/economía , Cobertura del Seguro/ética
2.
Br J Haematol ; 201(5): 935-939, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36846905

RESUMEN

The CD38-targeting monoclonal antibodies (CD38 mAbs) are well-established therapies in multiple myeloma (MM), but responses to treatment are not always deep or durable. Natural killer (NK) cells deficient in Fc epsilon receptor gamma subunits, known as g-NK cells, are found in higher numbers among individuals exposed to cytomegalovirus (CMV) and are able to potentiate the efficacy of daratumumab in vivo. Here, we present a single-centre, retrospective analysis of 136 patients with MM with known CMV serostatus who received a regimen containing a CD38 mAb (93.4% daratumumab and 6.6% isatuximab). CMV seropositivity was associated with an increased overall response rate to treatment regimens containing a CD38 mAb (odds ratio 2.65, 95% confidence interval [CI] 1.17-6.02). However, CMV serostatus was associated with shorter time to treatment failure in a multivariate Cox model (7.8 vs. 8.8 months in the CMV-seropositive vs. CMV-seronegative groups respectively, log-rank p = 0.18, hazard ratio 1.98, 95% CI 1.25-3.12). Our data suggest that CMV seropositivity may predict better response to CD38 mAbs, although this did not correspond to longer time to treatment failure. Larger studies directly quantitating g-NK cells are required to fully understand their effect on CD38 mAb efficacy in MM.


Asunto(s)
Infecciones por Citomegalovirus , Mieloma Múltiple , Humanos , Mieloma Múltiple/tratamiento farmacológico , Estudios Retrospectivos , Citomegalovirus , ADP-Ribosil Ciclasa 1 , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales/farmacología , Infecciones por Citomegalovirus/tratamiento farmacológico
3.
medRxiv ; 2020 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-32577672

RESUMEN

The current COVID-19 pandemic has spurred concern about what interventions may be effective at reducing transmission. The city and county of San Francisco imposed a shelter-in-place order in March 2020, followed by use of a contact tracing program and a policy requiring use of cloth face masks. We used statistical estimation and simulation to estimate the effectiveness of these interventions in San Francisco. We estimated that self-isolation and other practices beginning at the time of San Francisco's shelter-in-place order reduced the effective reproduction number of COVID-19 by 35.4% (95% CI, -20.1%-81.4%). We estimated the effect of contact tracing on the effective reproduction number to be a reduction of approximately 44% times the fraction of cases that are detected, which may be modest if the detection rate is low. We estimated the impact of cloth mask adoption on reproduction number to be approximately 8.6%, and note that the benefit of mask adoption may be substantially greater for essential workers and other vulnerable populations, residents return to circulating outside the home more often. We estimated the effect of those interventions on incidence by simulating counterfactual scenarios in which contact tracing was not adopted, cloth masks were not adopted, and neither contact tracing nor cloth masks was adopted, and found increases in case counts that were modest, but relatively larger than the effects on reproduction numbers. These estimates and model results suggest that testing coverage and timing of testing and contact tracing may be important, and that modest effects on reproduction numbers can nonetheless cause substantial effects on case counts over time.

4.
Science ; 365(6455): 786-793, 2019 08 23.
Artículo en Inglés | MEDLINE | ID: mdl-31395745

RESUMEN

How cellular and organismal complexity emerges from combinatorial expression of genes is a central question in biology. High-content phenotyping approaches such as Perturb-seq (single-cell RNA-sequencing pooled CRISPR screens) present an opportunity for exploring such genetic interactions (GIs) at scale. Here, we present an analytical framework for interpreting high-dimensional landscapes of cell states (manifolds) constructed from transcriptional phenotypes. We applied this approach to Perturb-seq profiling of strong GIs mined from a growth-based, gain-of-function GI map. Exploration of this manifold enabled ordering of regulatory pathways, principled classification of GIs (e.g., identifying suppressors), and mechanistic elucidation of synergistic interactions, including an unexpected synergy between CBL and CNN1 driving erythroid differentiation. Finally, we applied recommender system machine learning to predict interactions, facilitating exploration of vastly larger GI manifolds.


Asunto(s)
Epistasis Genética , Análisis de Secuencia de ARN/métodos , Análisis de la Célula Individual/métodos , Apoptosis/genética , Sistemas CRISPR-Cas , Proteínas de Unión al Calcio/genética , Puntos de Control del Ciclo Celular/genética , Línea Celular Tumoral , Células Eritroides/citología , Eritropoyesis/genética , Femenino , Perfilación de la Expresión Génica , Granulocitos/citología , Humanos , Proteínas de Microfilamentos/genética , Proteínas Proto-Oncogénicas c-cbl/genética , Calponinas
5.
Sci Signal ; 12(583)2019 05 28.
Artículo en Inglés | MEDLINE | ID: mdl-31138768

RESUMEN

Inhibitors targeting KRASG12C, a mutant form of the guanosine triphosphatase (GTPase) KRAS, are a promising new class of oncogene-specific therapeutics for the treatment of tumors driven by the mutant protein. These inhibitors react with the mutant cysteine residue by binding covalently to the switch-II pocket (S-IIP) that is present only in the inactive guanosine diphosphate (GDP)-bound form of KRASG12C, sparing the wild-type protein. We used a genome-scale CRISPR interference (CRISPRi) functional genomics platform to systematically identify genetic interactions with a KRASG12C inhibitor in cellular models of KRASG12C mutant lung and pancreatic cancer. Our data revealed genes that were selectively essential in this oncogenic driver-limited cell state, meaning that their loss enhanced cellular susceptibility to direct KRASG12C inhibition. We termed such genes "collateral dependencies" (CDs) and identified two classes of combination therapies targeting these CDs that increased KRASG12C target engagement or blocked residual survival pathways in cells and in vivo. From our findings, we propose a framework for assessing genetic dependencies induced by oncogene inhibition.


Asunto(s)
Neoplasias Pulmonares/metabolismo , Neoplasias Pancreáticas/metabolismo , Proteínas Proto-Oncogénicas p21(ras)/antagonistas & inhibidores , Animales , Antineoplásicos/farmacología , Sistemas CRISPR-Cas , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cisteína/genética , Femenino , Genómica , Células HEK293 , Humanos , Neoplasias Pulmonares/genética , Ratones , Ratones Desnudos , Mutación , Trasplante de Neoplasias , Oncogenes , Neoplasias Pancreáticas/genética , Unión Proteica , Proteómica , Proteínas Proto-Oncogénicas p21(ras)/genética , Análisis de Secuencia de ARN , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA